Among these, cyclooxygenase (COX) inhibitors, particularly selective COX-2 inhibitors, have gained significant attention due to their ability to reduce inflammation while minimizing ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

A meaningful rank of NSAIDs in terms of inhibition of COX should take into account the complexities inherent in biochemical systems, including the mechanism of catalysis of the endogenous substrate.

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

or in the the APC or APPROVE trials. Controversy about the mechanisms of potential cardiovascular side effects of COX inhibitors and NSAIDs persists. Intriguingly, the sulfone COX2 inhibitors ...

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Journavx, the first new class of pain medication in more ...

The drug, known as suzetrigine, is the first new painkiller approved in the U.S. since 1998. It can be used to relieve pain after surgery or injury, and some researchers say it might be the start of a ...

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...

pylori infection, but were less likely to have dyspepsia compared with H2RA users. PPI users were also more likely to have been prescribed NSAIDs, COX-2 inhibitors and SSRIs. Overall, most H2RA users ...

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.